# Drug Development in Biotech: From Discovery to Approval Canonical URL: https://biopharmsignal.com/blog/biotech-drug-development-overview-from-discovery-to-approval Published: 2026-03-30 Category: Clinical Trials Tags: Drug Development, Discovery, Clinical Trials, FDA Approval, Biotech Basics Summary: Learn the full biotech drug development process from discovery to approval, including preclinical work, clinical phases, filing, review, and launch. Drug development in biotech is a long process that turns a scientific idea into a potential medicine. It usually begins with discovery, moves through preclinical work, then proceeds through clinical trials, regulatory filing, and finally FDA review and approval if the program succeeds. Each stage has a different purpose, different risks, and different news signals. Understanding the full process is essential for biotech investors because the market often reacts not just to results, but to where a program sits in the development chain. A headline about Phase 1 data means something very different from a headline about FDA approval or a commercial launch. The path from discovery to approval is the backbone of biotech news. ## Discovery and target selection The process starts with discovery. Scientists identify a biological target, a pathway, or a mechanism that may be relevant to a disease. They then design molecules or biologics that could alter that biology. At this stage, the work is mostly about hypothesis generation and early validation. Investors may not see much public information yet, but discovery is where the story begins. If the scientific rationale is strong, the company may move into preclinical testing. This is where the candidate is evaluated in lab and animal models to understand potential activity, safety, and dosing considerations before human testing begins. ## Preclinical development Preclinical work is a filtering stage. The company wants to know whether the candidate is strong enough to justify a clinical program. Researchers study pharmacology, toxicology, exposure, and mechanism. They also begin thinking about how the drug might be formulated and delivered. If the candidate fails here, it never reaches patients. This stage matters because it builds the foundation for the IND submission. It also informs the clinical design that follows. Even though investors may not get frequent headlines at this point, preclinical success can still shape the market’s long-term view of a platform. ## IND and the start of clinical testing Once enough preclinical work is complete, the company submits an IND, or Investigational New Drug application, to the FDA. If the agency allows the trial to proceed, the company can begin clinical testing in humans. This is a major milestone because it moves the program from theoretical science into actual human data generation. From this point on, the news flow becomes much more visible. Clinical enrollment updates, protocol amendments, readout windows, and safety commentary all start to matter to the market. ## Phase 1, Phase 2, and Phase 3 Clinical development usually proceeds through Phase 1, Phase 2, and Phase 3. Phase 1 focuses mainly on safety and dose. Phase 2 looks for early evidence of efficacy and helps refine the dose or patient population. Phase 3 is the late-stage test that often provides the data needed for approval. Each phase is a catalyst stage because each one can change the probability of success. The market often reacts most strongly to Phase 2 and Phase 3 because those stages are closer to a regulatory decision. But Phase 1 can still matter a great deal if the program is early or the company is built around a single asset. ## Filing and review If the data package is strong enough, the company submits an NDA or BLA to the FDA. That begins the formal review process. The agency may assign a PDUFA date, hold an advisory committee meeting, request more information, or proceed to approval. This is where regulatory milestones become especially important because they are tied to a known review timeline. The filing stage is often when biotech news becomes more concentrated. The market wants to know whether the application has been accepted, whether the review is standard or priority, and whether any warning signs appear before the target action date. ## Approval and commercialization If the FDA approves the product, the company moves into commercialization. That is a major shift because the value story changes from "can it work?" to "can it be sold effectively?" Launch execution, reimbursement, physician adoption, manufacturing, and commercial partnerships all become part of the news flow. Approval is not the end of drug development. It is the start of the commercial phase. New indication work, label expansions, post-marketing commitments, and lifecycle management continue to shape the stock after launch. ## Why the full pipeline matters for investors Investors need the entire development overview because each stage creates a different kind of risk and a different kind of catalyst. A discovery story is about scientific potential. A clinical story is about evidence. A regulatory story is about timing and approval probability. A commercial story is about execution and growth. If you know where a drug sits in the pipeline, you can understand why a headline matters and what the next major milestone should be. That context is what turns biotech news into actionable information. ## Final takeaway Biotech drug development is a long journey from discovery to approval. Each stage has its own technical, regulatory, and commercial challenges, and each stage creates its own news flow. For investors and industry watchers, understanding that full sequence is the key to interpreting catalyst-driven biotech news correctly. In this sector, the pipeline is the story. The better you understand the stages, the better you can understand the headlines.